EP-1331: Diabetes and metformin influence survival in glioblastoma patients

Prognosis and Survival Study in Patients with Glioblastoma Multiform and Its Relationship with EGFR Expression

Background and Aim: Glioblastoma multiforme (GBM) is the most common malignant and invasive tumor of the brain. The relation between prognosis and survival of GBM patients with Epidermal Growth Factor Receptor (EGFR) expression is challenging. Thus, we aimed to evaluate the prognosis and survival of patients with GBM and its relationship with EGFR expression. Materials and Methods: This single...

Pharmacogenetic variation of SLC47A1 gene and metformin response in type2 diabetes patients

Type 2 diabetes mellitus is a worldwide epidemic disorder with considerable health and economic consequences. Metformin is one of the most commonly prescribed oral antidiabetic drugs. Pharmacogenetic studies showed that variants in genes related to the pharmacokinetics of metformin were associated with glucose-lowering effect of metformin. The aim of this study was to evaluate pharmacogenetic v...

Survival in patients with glioblastoma receiving valganciclovir.

Metformin and Not Diabetes Influences the Survival of Resected Early Stage NSCLC Patients.

BACKGROUND Published data suggest that diabetes influences survival of patients with lung cancer. The anti-cancer effect of metformin confounds this association. We sought to study the association of diabetes and metformin with survival in patients undergoing resection of stage I non-small cell lung cancer (NSCLC). METHODS Pathologic stage I NSCLC patients undergoing anatomic resection from 2...

Sulfonylureas (not metformin) improve survival of patients with diabetes and resectable pancreatic adenocarcinoma: erratum